メンブレンクロマトグラフィーの世界市場予測（～2022年）：商品別（消耗品（カプセル・カートリッジ）、シリンジフィラー、メンブレンフィルター、スピンカラム）、付属品）、技術別（イオン交換、アフィニティ（陰イオン）、疎水性相互作用）、オペレーション形態別（フロースルー式）

2018年2月27日 // 0 Comments

“The global membrane chromatography market is projected to grow at a CAGR of 18.1%.”
The global membrane chromatography market is expected to reach USD 290.6 million by 2022 from USD 126.6 million in 2017, at a CAGR of 18.1%. Growth in this market can primarily be attributed to factors such as increasing demand for biopharmaceuticals, increasing R&D expenditure in the biopharmaceutical industry, significant benefits of membrane chromatography over conventional chromatography methods, and increasing regulatory scrutiny on the cleaning validation of downstream purification processes. However, the limited use of membrane chromatography in large-scale manufacturing is expected to restrain the growth of this market during the forecast period.

“The ion exchange membrane chromatography segment is expected to account for the largest share in 2017.”
Based on techniques, the membrane chromatography market is segmented into ion exchange membrane chromatography, affinity membrane chromatography, and hydrophobic interaction membrane chromatography. The ion exchange membrane chromatography segment is expected to account for the largest share of the global membrane chromatography market in 2017. The large share of this segment can be attributed to its wide applications in antibody polishing and virus purification due to the advantages associated with ion exchange membrane chromatography, such as scalability, robustness, disposable nature, high throughput, rapid processing, reduced buffer consumption, and a validation-free environment.
Based on product, the consumables segment is expected to dominate the market in 2017
In 2017, the membrane chromatography consumables segment is expected to account for the largest share of the global market. Growth in this segment can primarily be attributed to the increasing use of capsules and cartridges for purification applications in biomanufacturing and lab-scale production and process development processes.
“North America is expected to account for the largest share during the forecast period.”
By region, North America is expected to account for the largest share of the global membrane chromatography market. This large share can be attributed to the increasing demand for biopharmaceuticals and rising R&D expenditure by biopharmaceutical companies in North America. Europe is expected to account for the second-largest share of the membrane chromatography market.
Break-up profile of primaries:
• By Company Type- Tier 40%, Tier 30%, and Tier 30%
• By Designation-C-level-27%, D-level-18%, and Others-55%
• By Region-North America-50%, Europe-20%, Asia Pacific-20%, and RoW-10%
The key players in the global membrane chromatography market are Sartorius (Germany), GE Healthcare (US), Danaher (US), Merck Millipore (US), and 3M (US).
Research Coverage:
The membrane chromatography market in this report is segmented by product, technique, operation mode, and region. The study tracks and analyzes competitive developments such as product launches, collaborations, agreements, partnerships, and acquisitions, and profiles key players and core competencies in the membrane chromatography market.
Reasons to buy this report:
The report provides insights on the following pointers:
Market Penetration: Comprehensive information on portfolios offered by the top players in the global membrane chromatography market. The report analyzes the market by product, technique, operation mode, and region

Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and product launches in the global membrane chromatography market

Market Development: Comprehensive information about lucrative emerging markets—the report analyzes the markets for membrane chromatography products across regions

Market Diversification: Exhaustive information about new products, untapped geographies, and recent developments in the global membrane chromatography market

Competitive Assessment: In-depth assessment of strategies, products, and manufacturing capabilities of the key players in the global membrane chromatography market

体内 (in vivo) 毒性の世界市場予測（～2022年）：商品別（器機、消耗品（動物モデル、試薬と道具））、テストタイプ別（慢性、亜慢性）、毒性評価項目別（免疫毒性、全身毒性、発生・生殖毒性）、テスト施設別（外部委託、社内）

2018年2月27日 // 0 Comments

“The global in vivo toxicology market is projected to grow at a CAGR of 6.9%.”
The in vivo toxicology market is expected to reach USD 6.14 billion by 2022 from an estimated USD 4.40 billion in 2017, at a CAGR of 6.9%. The key factors driving the growth of this market include, increasing pharmaceutical R&D activities, mandatory government regulations for animal testing, innovations in animal models, and the development of exclusive in vivo toxicology tests. On the other hand, alternative methods to animal testing and disadvantages associated with animal toxicology testing likely to restrain the growth of this market.

“The instruments segment is expected to grow at the highest CAGR during the forecast period”
On the basis of product, the in vivo toxicology market is segmented into consumables and instruments. The consumables segment is further divided into reagents & kits and animal models. The instruments segment is expected to grow at the highest rate during the forecast period. The growth of this segment can be attributed to the increasing research on biological samples (such as blood and urine) using bioanalytical equipment.

“Chronic toxicity testing holds the largest share in the global in vivo toxicology market by testing type”
Based on testing type, the global in vivo toxicology market is segmented into acute, sub-acute, sub-chronic, and chronic toxicity testing. In 2017, chronic toxicity testing segment is estimated to hold the largest share in the global in vivo toxicology market. The large share of this market is attributed to the high cost of in vivo testing for more than 90 days, maintaining the animals, quality of tests, and the long duration of the tests performed.

“The immunotoxicity segment is expected to grow at the highest CAGR during the forecast period.”
On the basis of toxicity endpoint, the global in vivo toxicology market is segmented into immunotoxicity, systemic toxicity, carcinogenicity, genotoxicity, developmental and reproductive toxicity (DART), and other toxicity endpoints (includes organ toxicity, endocrine disruptor toxicity, juvenile toxicity, phototoxicity, ocular toxicity, and skin irritation). In 2017, the immunotoxicity segment is expected to account for the largest share in the in vivo toxicology market, this segment is also expected to grow at the highest CAGR during the forecast period. Rising demand for the development of biologics for autoimmune diseases and cancer and the increasing growth of biosimilars in oncology are driving the growth of this segment.

“China to witness the highest growth in the APAC region during the forecast period (2017-2022)”
In the APAC region, China is expected to witness the highest growth during the study period. The rising R&D funding and collaborations; initiatives taken by the Chinese government to promote life science research; and the strong trend of commercialization of biotechnology research are contributing to the growth of in vivo toxicology market in China.

Break of primary participants was as mentioned below:
• By Company Type – Tier 1–29%, Tier 2–35% and Tier 3–36%
• By Designation – C-level–39%, Director Level–35%, Others–26%
• By Region – North America–42%, Europe–36%, Asia Pacific–13%, RoW–9%

The major players in the global in vivo toxicology market are Thermo Fisher (US), Danaher (US), Charles River (US), Covance (LabCorp), and The Jackson Laboratory (US).
Research Coverage:
The report analyzes the in vivo toxicology market and aims at estimating the market size and future growth potential of this market based on various aspects such as products, testing type, toxicity endpoint, testing facility and region. The report also includes the competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
The report will help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in-turn would help them, garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their position in the market.
This report provides insights on the following pointers:
• Market Penetration: Comprehensive information on product portfolios offered by key players in the global in vivo toxicology market. The report analyzes the global in vivo toxicology market by product, testing type, toxicity endpoint, testing facility, and region
• Product and Service Innovation: Detailed insights on upcoming trends and product and service launches in the global in vivo toxicology market
• Market Development: Comprehensive information about the lucrative emerging markets by product, testing type, toxicity endpoint, testing facility, and region
• Market Diversification: Exhaustive information about new products, growing geographies, recent developments, and investments in the global in vivo toxicology market
• Competitive Assessment: In-depth assessment of market shares and growth strategies of leading players in the global market

マイクロプレートシステムの世界市場予測（～2022年）：商品別（リーダー (マルチモード (ハイブリッド)・シングルモード)・ディスペンサー・ソフトウェア）、用途別（研究、臨床診断）、エンドユーズ別（バイオテクノロジー、医薬品、病院、診断ラボ）

2018年2月27日 // 0 Comments

“The global microplate systems market projected to grow at a CAGR of 4.0%.”
The global microplate systems market is expected to reach USD 996.9 million by 2022 from USD 820.3 million in 2017 at a CAGR of 4.0%. This market is experiencing significant growth due to increasing R&D expenditure in the pharmaceutical industry, increasing focus on miniaturization, technological advancements, and growing prevalence of diseases.

“Microplate Readers are expected to grow at the highest CAGR during the forecast period.”
Based on product and service, the market is segmented into microplate readers, microplate pipetting systems and dispensers, microplate washers, and other products. The microplate readers segment is expected to hold the largest share of the market in 2017 and projected to register the highest CAGR during the forecast period. High demand for these systems due to increasing number of research activities are the key factors driving the growth of this segment.

“Biotechnology and pharmaceutical companies is expected to dominate the market during the forecast period.”
Based on end user, the market is segmented into biotechnology and pharmaceutical companies, hospitals and diagnostic laboratories, and research and academic institutes. The biotechnology and pharmaceutical companies segment is estimated to hold the largest share the microplate systems market in 2017. It is projected to register the highest growth during the forecast period due to increasing government support in the form of funding for biotech and pharma research.

“Asia Pacific to witness the highest growth during the forecast period.”
In 2017, North America is expected to account for the largest share of the market followed by Europe. However, Asia Pacific is expected to register the highest CAGR during the forecast period. This can be attributed to factors such as the growing focus on research-related funding activities by government organizations, increasing healthcare investments, increasing ageing population, and increasing prevalence of diseases.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 – 30%; Tier 2 – 42%; Tier 3 – 28%
• By Designation: C-level- 25%; D-level- 45%; Others- 30%
• By Region: North America-48%; Europe-29%; Asia Pacific-20%; Latin America- 19%, Rest of the World-4%

List of companies profiled in the report
• BioTek (US)
• Danaher (US)
• PerkinElmer (US)
• Tecan (Switzerland)
• Thermo Fisher (US)
• BMG LABTECH (Germany)
• BERTHOLD (Germany)
• Agilent (US)
• Bio-Rad (US)
• Promega (US)
• Biochrom (UK)
• Corning (US)
• Lonza (Switzerland)
• Rayto (China)
• Mindray (China)
Research Coverage:
The report provides an overview of the microplate systems market. It aims at estimating the market size and future growth potential of this market across different segments such as product, application, end user, and region. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help the market leaders/new entrants in this market by providing them with the closest approximations of revenues for the overall microplate systems market and its subsegments. This report will help stakeholders to understand the competitive landscape better and gain insights to position their businesses and help companies make suitable go-to-market strategies. The report also will also help stakeholders understand the pulse of the market and provide them with information regarding key market drivers and opportunities.

ガイドワイヤーの世界市場予測（～2022年）：材料別（ニチノール、ステンレス鋼、ハイブリッド）、商品別（外科、診断（親水性、疎水性））、用途別（循環器、血管、神経、GIT、ENT、泌尿器、腫瘍）、エンドユーザー別（病院、ASC）

2018年2月27日 // 0 Comments

The guidewires market projected to grow at a CAGR of 4.8%
The global guidewires market is projected to reach USD 764.0 million by 2022 from USD 605.2 million in 2017, at a CAGR of 4.8%. The growth witnessed by guidewires is mainly driven by growing target disease incidence, continuous product commercialization by major manufacturers and favorable medical reimbursements for guidewires in developed countries. The government initiatives to control the burden of healthcare-associated infections (HAIs) in developed countries and the increasing healthcare expenditure across emerging markets are also driving the growth of the market. However, high cost of surgical guidewires, spending cuts & excise duties on medical devices and dearth of skilled surgeons for minimally invasive surgeries are the key challenges faced by a majority of the guidewires manufacturers across the globe.
“The hybrid guidewires segment is poised to be the fastest-growing during the forecast period.”
On the basis of material, the global guidewires market is segmented into nitinol guidewires, stainless steel guidewires, and hybrid guidewires. The hybrid guidewires segment is expected to grow at the highest CAGR during the forecast period. This growth can be attributed to rising adoption among medical professionals owing to their technological and procedural advantages, growing awareness among surgeons about the clinical benefits of these guidewires, and the evolving reimbursement scenario for target procedures across key healthcare markets.
“The cardiology applications segment is poised to be the fastest-growing during the forecast period.”
On the basis of application, the global guidewires market is segmented into cardiology, vascular, neurology, urology, gastroenterology, oncology, and otolaryngology. The cardiology applications segment is expected to grow at the highest CAGR during the forecast period. This growth can be attributed to the rising adoption of guidewires among cardiologists owing to procedural and technical benefits offered by nitinol materials used for manufacturing cardiology guidewires.

“Asia Pacific is expected to register the highest growth rate during the forecast period.”
Geographically, the guidewires market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The highest CAGR for the APAC guidewires market can be attributed to the rising adoption of guidewires due to their decreasing costs (owing to the increase in localized manufacturing and strengthening of distribution networks of key product manufacturers) and increasing healthcare expenditure across key APAC countries.

Breakdown of supply-side primary interviews: by company type, designation, and region:
• By Company Type – Tier 1 – 25%, Tier 2 – 30% and Tier 3 – 45%
• By Designation – C level – 26%, Director level – 30%, Others – 44%
• By Region – North America – 34%, Europe – 26%, APAC – 23%, RoW – 17%

The global guidewires market is competitive, with a large number of global and local players. In 2016, the market was dominated by Boston Scientific (US), Medtronic (Ireland), Abbott (US), Cook Group (US), and Terumo (Japan). Product launches, market expansions, strategic acquisitions, partnerships, agreements & collaborations were the major strategies adopted by market players to achieve growth in the market.

Research Coverage
This report studies the guidewires market based on material, product, application, and end user. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It analyzes opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for the market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends, prospects, and contributions to the total market. The report forecasts the revenue of the market segments with respect to four main regions.

Reasons to Buy the Report:
From an insights perspective, this research report has focused on various levels of analysis—industry trends, market share analysis of top players, and company profiles, which together comprise and discuss basic views on the competitive landscape, emerging and high-growth segments of the guidewires market, and high-growth regions and countries and their respective drivers, restraints, challenges, and opportunities.

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn help firms garner greater market shares. Firms purchasing the report could use any one or a combination of the belowmentioned five strategies for strengthening their market shares.

The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on product portfolios offered by the major players in the guidewires market. The report analyzes the guidewires market based on material, product, application, end user, and region
• Product Development: Detailed insights on the research and development activities and product launches in the guidewires market
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various guidewires across geographies.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the guidewires market
• Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of leading players in the guidewires market

オリゴヌクレオチド合成の世界市場予測（～2022年）：商品別（プライマー、プローブ、リンカー、アダプター、カスタムオリゴ、試薬、機器）、用途別（PPCR、DNA、RNAi、研究、治療)、エンドユーザー別（学術研究機関、医薬品、バイオテクノロジー）

2018年2月27日 // 0 Comments

“The global oligonucleotide synthesis market projected to grow at a CAGR of 10.9%.”
The global oligonucleotide synthesis market is expected to reach USD 2.46 billion by 2022 from USD 1.47 billion in 2017 at a CAGR of 10.9%. This market is experiencing significant growth due to the increasing research activities in the pharma and biotech sectors and the rising demand for innovative diagnostic and therapeutic techniques.
Growth in this market is mainly driven the increasing R&D expenditure by pharmaceutical and biotechnology companies, rising demand for synthesized oligonucleotides from the growing field of molecular diagnostics, rising venture capital investments, and increasing demand for synthetic genes. However, the price erosion of synthesized oligos and lack of regulations for therapeutic oligos are some factors that may hinder the growth of this market.

“Synthesized oligonucleotides are expected to grow at the highest CAGR during the forecast period.”
Based on product, the market is segmented into synthesized oligonucleotides, reagents, and equipment. The synthesized oligonucleotides segment is expected to grow at the highest CAGR during the forecast period The increasing number of applications of synthesized oligonucleotides in research, diagnostics, and therapeutics is a key market driver in this segment. The rising availability and demand for custom oligos also contribute to the growth of the synthesized oligonucleotides market.

“The research segment is expected to hold the largest share of the market in 2017.”
Based on application, the market is segmented into research, diagnostics, and therapeutics. The research segment is estimated to hold the largest share of the oligonucleotide synthesis market in 2017. The market growth for research applications is mainly driven by the developments in the fields of gene synthesis and NGS. Oligos are widely used in technologies such as PCR, qPCR, gene synthesis, isothermal nucleic acid amplification technology (INAAT), microarray, hybridization, DNA sequencing, and next-generation sequencing (NGS).

“Academic research institutes are expected to dominate the market during the forecast period.”
Based on end user, the market is segmented into academic research institutes, pharmaceutical and biotechnology companies, diagnostic laboratories, and other end users. The academic research institutes segment is expected to dominate the market during the forecast period. With the increasing funding pouring into institutes to conduct research, the demand for oligonucleotides is bound to increase. To meet this need, companies are launching products and entering into agreements with different research institutes to supply oligonucleotides for research purposes. For instance, in August 2015, Eurofins Genomics launched NGS tests for the identification of non-targeted microorganisms, including 16S Microbiome Profiling for academia and research.

“APAC to witness the highest growth during the forecast period.”

In 2017, North America is expected to account for the largest share of the market followed by Europe. However, Asia Pacific is expected to register the highest CAGR during the forecast period. This can be attributed to factors such as the growing availability of synthesized oligos, along with an increase in R&D funding and activities in the APAC region. The increasing focus of prominent players on APAC is also supporting market growth in the region.
The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 – 36%; Tier 2 – 46%; Tier 3 – 18%.
• By Designation: C-level- 26%; D-level- 45%; Others- 29%.
• By Region: North America-41%; Europe-31%; Asia Pacific-20%; Latin America- 5%, Middle East and Africa-3%

List of companies profiled in the report
• Agilent Technologies (US)
• ATDBio (UK)
• Bio-Synthesis (US)
• BioAutomation (US)
• LGC Biosearch Technologies (US)
• Eurofins Genomics (Germany)
• Eurogentec (Belgium)
• GeneDesign (Japan)
• GE Healthcare (US)
• GenScript (US)
• Integrated DNA Technologies (IDT) (US)
• Nitto Denko Avecia (US)
• Thermo Fisher Scientific (US)
• TriLink Biotechnologies (US)
• Sigma-Aldrich Corporation (Sigma-Aldrich) (US) (part of Merck KGAA (Germany)
Research Coverage:
The report provides an overview of the oligonucleotide synthesis market. It aims at estimating the market size and future growth potential of this market across different segments such as product, application, end user, and region. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help the market leaders/new entrants in this market by providing them with the closest approximations of revenues for the overall oligonucleotide synthesis market and its subsegments. This report will help stakeholders to understand the competitive landscape better and gain insights to position their businesses and help companies make suitable go-to-market strategies. The report also will also help stakeholders understand the pulse of the market and provide them with information regarding key market drivers and opportunities.

CROサービスの世界市場予測（～2023年）：タイプ別（創薬研究、ＣＭＣ、前臨床、臨床研究、ラボサービス）、治療領域別（腫瘍、CNS、心臓血管）、エンドユーザー別（医薬品と医療機器）

2018年2月27日 // 0 Comments

“The Contract Research Organization (CRO) services market is projected to grow at a CAGR of 7.6% between 2018 and 2023.”
The CRO services market is expected to reach USD 56.34 billion by 2023 from USD 39.13 billion in 2018, at a CAGR of 7.6%. Increased outsourcing of R&D activities and increasing number of clinical trials are some of the major factors driving the growth of this market. However, intense competition in the CRO services market is one of the major challenges for the players operating in the CRO services market.
“Laboratory services segment to witness the highest growth rate during the forecast period.”
Among the CRO services, the laboratory services segment is expected to register the highest CAGR during the forecast period. The high growth of this segment is attributed to the increasing number of pipeline drugs and growing outsourcing of laboratory services by pharmaceutical and biopharmaceutical companies.
“Oncology segment to grow at the highest CAGR from 2018 to 2023.”
Oncology segment is expected to register the highest CAGR during the forecast period. The increasing number of clinical trials and rising prevalence of cancer worldwide are the major factors supporting its growth during the forecast period.
“APAC to witness the highest growth rate during the forecast period.”
The Asia Pacific region is expected to witness the highest CAGR during the forecast period, owing the rapid growth in the pharmaceutical and biopharmaceutical industry, low cost of clinical trials, rising number of CROs, and favorable government policies in the region.
Break of primary participants:
• By Company Type – Tier 1: 21%, Tier 2–26%, and Tier 3–53%
• By Designation – C Level: 32%, Director Level: 26%, and Others: 42%
• By Region – North America: 26%, Europe: 35%, Asia Pacific: 20%, Latin America: 11%, and the Middle East & Africa: 8%
Research Coverage:
The report analyzes the various CRO services and their adoption patterns in the market. It aims at estimating the market size and future growth potential of the global CRO services market for different segments such as type, therapeutic area, end user, and region. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, service offerings, recent developments, and key market strategies.
Reasons to Buy the Report:
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help garner a greater share. Firms purchasing the report could use any one or combination of the below-mentioned strategies for strengthening their market positions.
The report provides insights on the following pointers:
 Market Penetration: Comprehensive information on the service portfolios offered by the top players in the CRO services market
 Service Launch/Innovation: Detailed insights on new service launches in the CRO services market
 Market Development: Comprehensive information about lucrative emerging markets, by type, therapeutic area, end user, and region
 Market Diversification: Exhaustive information about new services, growing geographies, recent developments in the CRO services market
 Competitive Assessment: In-depth assessment of growth strategies, services, and manufacturing capabilities of leading players in the CRO services market

血漿分画製剤の世界市場予測（～2023年）：商品別（IVIG(静注免疫グロブリン)、アルブミン、第VIII因子、フォンヴィレブラント因子、PCC (プロトロンビン複合体製剤)、プロテアーゼ阻害剤）、用途別（免疫療法、血液疾患、救命治療、リウマチ）、エンドユーザー別（病院、クリニック、学術研究機関）

2018年2月27日 // 0 Comments

The plasma fractionation market is projected to reach to USD 29.50 billion by 2023 from an estimated USD 21.23 billion in 2018. The growing geriatric population across the globe, increasing use of immunoglobulins in various therapeutic areas, growing prevalence of respiratory diseases and uptake of alpha-1-antitrypsin, and increase in plasma collection are the factors driving this market. However, the emergence of recombinant alternatives, high cost of plasma products, and limited reimbursement may hinder the growth of this market.

The protease inhibitors segment is expected to grow at the highest CAGR during the forecast period
On the basis of product, the plasma fractionation market is segmented into immunoglobulins, coagulation factor concentrates, albumin, protease inhibitors, and other plasma products. The protease inhibitors segment is expected to witness the highest growth during the forecast period. The high growth of this segment is primarily attributed to the increasing prevalence of alpha-1 antitrypsin deficiency and increasing number of various respiratory diseases.

The pulmonology segment is projected to witness the highest growth during the forecast period
Based on the application, the plasma fractionation market is classified into neurology, immunology, hematology, critical care, pulmonology, hemato-oncology, rheumatology, and other applications. The pulmonology segment
is expected to grow at the highest CAGR during the forecast period. This can largely be attributed to the increasing use of immunoglobulins and protease inhibitors in the treatment of various respiratory diseases such as AATD and COPD, asthma, and respiratory tract infections.

The hospitals and clinics segment is expected to grow at the highest CAGR during the forecast period
On the basis of type of end user, the market is segmented into hospitals & clinics, clinical research laboratories, and academic institutes. During the forecast period, the hospitals & clinics segment is expected to grow at the highest CAGR. The high growth of this segment can be attributed to the increasing adoption of plasma products in the treatment of various immunological, neurological, and bleeding disorders; large patient pool treated in hospitals; growing number of hospitals & clinics across the globe; and increasing number of collaborations between the manufacturers of plasma products and hospitals.

Asia Pacific to witness the highest growth during the forecast period
Asia Pacific is expected to witness the highest growth during the forecast period (2018 to 2023). The region’s large geriatric population, large population, improving healthcare infrastructure, increasing incidences of immunological and bleeding diseases, increasing focus diagnosis and prophylactic treatment, and increasing awareness about technologically advanced products are driving the growth of this market.

Break of primary participants was as mentioned below:
• By Company Type – Tier 1–46%, Tier 2–33% and Tier 3–21%
• By Designation – C Level–43%, Director Level–35%, Others–22%
• By Region – North America–34%, Europe–26%, Asia Pacific–24%, Latin America–12%, Middle East and Africa- 4%
Some of the major market players in the plasma fractionation market are CSL (Australia), Grifols (Spain), Shire (Ireland), Octapharma (Switzerland), Kedrion (Italy), Bio Product Laboratory (UK), Sanquin (Netherlands), LFB (France), Biotest (Germany), Japan Blood Products Organization, China Biologic Products (China), Green Cross Corporation (South Korea), and Shanghai RAAS Blood Products (China).
Research Coverage:
The report analyzes the plasma fractionation market and aims at estimating the market size and future growth potential of this market based on various segments such as product, application, end user, and region. The report also includes a volume data analysis for various plasma products across the globe and a competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a greater share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:
• Market Penetration: Comprehensive information on product portfolios offered by the top players in the global plasma fractionation market. The report analyzes the global plasma fractionation market by product, application, end user, and region.
• Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global plasma fractionation market.
• Market Development: Comprehensive information on the lucrative emerging markets by product, application, end user, and region.
• Market Diversification: Exhaustive information about new products, growing geographies, recent developments, and investments in the global plasma fractionation market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of leading players in the global plasma fractionation market.

フローサイトメトリーの世界市場予測（～2022年）：技術、製品・サービス、用途、エンドユーザー

2018年2月23日 // 0 Comments

The global flow cytometry market is expected to reach USD 4.79 Billion by 2022 from USD 3.29 Billion in 2017, growing at a CAGR of 7.8% during 2017-2022. Factors such as the attributed to factors such as the continuous technological advancements in the field of flow cytometry, increasing incidence and prevalence of target diseases (such as HIV/AIDS and cancer), growing adoption of flow cytometry in advanced research activities and clinical trials, and increasing availability of novel application-specific flow cytometry products are driving the growth of the global market.
By technology, the global flow cytometry market is categorized into cell-based and bead-based flow cytometry. The bead-based technology segment is expected to grow at the highest CAGR during the forecast period, owing to the procedural advantages offered by this technology over other cell-based technology (enzyme-linked immunosorbent assay (ELISA) and western blot), such as the capacity to detect multiple analytes (also known as multiplexing), high reproducibility, stability, and speed.

On the basis of product and service, the market is categorized into reagents and consumables; instruments; services; software; and accessories. The reagents and consumables segment accounted for the largest share of the flow cytometry market in 2017. Factors such as the development and commercialization of high-quality application-specific reagents and assays and continuous requirement of flow cytometry reagents by end users are expected to drive the growth of the reagents and consumables market in the coming years.

By application, the global market is divided into research, clinical, and industrial applications. The clinical applications segment is expected to grow at the highest CAGR during the forecast period. The growth of this segment can be attributed to the growing usage of flow cytometry in organ transplantation, cancer diagnosis, and hematological disorder treatment.
By end user, the flow cytometry market is categorized into academic and research institutes, hospitals and clinical testing laboratories, and pharmaceutical and biotechnology companies. The hospitals and clinical testing laboratories segment is expected to grow at the highest rate during the forecast period.

Geographically, this market is classified into North America, Europe, Asia Pacific, and the Rest of the World. In 2017, the global market is expected to be dominated by North America, followed by Europe. However, the Asia Pacific region is expected to witness the fastest growth during the forecast period owing to the increasing participation of China, India, Japan, and South Korea in flow cytometry-based research; expansion of research infrastructure; and increasing public-private initiative aimed towards boosting advance research practices in this region.

Flow Cytometry Market

The growth of flow cytometry market mainly restrained by factors such as the high cost of flow cytometry instruments and a dearth of skilled professionals and insufficient knowledge regarding the use of flow cytometers.

Product launches and enhancements are the key growth strategies adopted by major players to strengthen their position in the global market. In addition, strategies such as partnerships and collaborations; acquisitions; and expansions were also adopted by several market players to strengthen their market position, expand their R&D capabilities, and geographic presence in the global flow cytometry market.

As of 2016, BD (US), Beckman Coulter (US), and Thermo Fisher Scientific (US), Merck KGaA (Germany), Sysmex Partec (Germany), Luminex Corporation (US), Miltenyi Biotec (Germany), Bio-Rad Laboratories (US), Sony Biotechnology (US), Agilent Technologies (US), ACEA Biosciences (US), biomérieux (France), Enzo Life Sciences (US), Stratedigm (US), and Apogee Flow Systems (UK), were some of the key players operating in the global flow cytometry market.

塞栓保護デバイスの世界市場予測（～2023年）：遠位フィルター、遠位咬合、近位閉塞

2018年2月23日 // 0 Comments

The global embolic protection device market is projected to reach USD 604.9 Million by 2023 from USD 405.5 Million in 2018, at a CAGR of 8.3%. Factors such as the rising incidence of cardiovascular and neurovascular diseases, growing funding and investments, launch of technologically advanced embolic protection devices, and rising demand for minimally invasive procedures are expected to drive the growth of the market. On the other hand, product failures and recalls may hinder the overall market growth to a certain extent during the forecast period.
In this report the global embolic protection device market is segmented on the basis of type & material, application, indication, end users and region. On the basis of type, the distal filter devices segment is expected to grow at the highest CAGR during the forecast period. The high growth of this segment can primarily be attributed to the procedural benefits distal filter devices offer, such as ease of use, enhanced visibility, and crossing profile of the device. On the basis of material, nitinol accounted for the largest share of the market. This segment is also expected to grow at the highest rate in the market. The super-elastic material and braided nitinol design provide full wall apposition and this quality is expected to drive the growth of nitinol in the global market during the forecast period.

On the basis of application, the embolic protection market is segmented into cardiovascular, neurovascular, and peripheral vascular diseases. According to this study, the neurovascular diseases segment is poised to grow at the fastest growth rate in the embolic protection device market. With the increasing target patient population, the demand for embolic protection devices for the treatment of neurovascular diseases is expected to increase during the forecast period.

Based on the indications, the embolic protection devices segment is further segmented into percutaneous coronary intervention, transcatheter aortic valve replacement (TAVR), carotid artery diseases, saphenous vein graft disease, and other indications. The percutaneous coronary intervention segment accounted for the largest share of the global market. The large share of this segment can primarily be attributed to the increasing prevalence of CAD and the rising preference for minimally invasive procedures.

Among end users, hospitals are the fastest growing end-user segment in the embolic protection device market during the forecast period. The market for this segment is mainly driven by factors such as the growing number of angioplasty procedures in hospitals, rising incidence of chronic vascular diseases, favorable reimbursement scenario in developed countries, increasing number of hospitals, and increasing government initiatives to provide quality treatment for cardiovascular diseases.

Embolic Protection Devices Market

Geographically, the embolic protection device market is segmented into North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. In 2017, North America dominated the global market. The rising geriatric population, prevalence of cardiovascular and neurovascular diseases, increasing adoption of minimally invasive techniques, increasing availability of funding, and presence of a large number of medical device product manufacturers are driving the growth of the embolic protection devices market in North America. Asia Pacific, on the other hand, is expected to grow at the highest CAGR during the forecast period due to the growing number of prescriptions for people aged 65 or above, increasing healthcare spending, rising healthcare costs, and increasing target population.

Prominent players in the embolic protection device market are Boston Scientific (US), Medtronic Ireland), Abbott (US), Cordis (A Cardinal Health Company) (US), Allium Medical Solutions (Israel), Contego Medical (US), W.L. Gore & Associates (US), Silk Road Medical (US), Claret Medical (US), and AngioSlide (Israel).

RSV診断の世界市場予測（～2022年）：キット、アッセイ、装置、方法、エンドユーザー

2018年2月23日 // 0 Comments

“The global RSV diagnostics market projected to grow at a CAGR of 10.1% during the forecast period”The RSV diagnostics market is expected to reach USD 929.2 million by 2022 from USD 574.3 million in 2017, at a CAGR of 10.1%. Factors driving the growth of this market include rising burden of RSV infections, growing demand for molecular diagnostic tests for the diagnosis of RSV infections, increasing adoption of point-of-care testing for RSV diagnosis and increasing approval of RSV diagnostic kits and assays. On the other hand, the development of RSV vaccine is expected to emerge as a biggest threat which would alter the market growth in the coming years.
“Kits and Assays are estimated to grow at the highest CAGR during the forecast period”
The products market is further segmented into kits and assays, instruments, and other products. The kits and assays segment is expected to account for the largest share and grow at the highest CAGR during the forecast period. Factors driving the growth of this segment include the increasing infection of RSV in newborn infants and young children and growing demand for kits and assays for RSV diagnosis
“The molecular diagnostics segment is estimated to grow at the highest CAGR during the forecast period”
The method market is further segmented into Rapid Antigen Detection Tests, molecular diagnostics, and others methods. The molecular diagnostics segment is expected to account for the largest share of the global RSV diagnostics market in 2017. Market growth can largely be attributed to factors such as the increasing demand for molecular diagnostic testing for RSV diagnosis.
“Asia Pacific is estimated to grow at the highest CAGR during the study period”
Geographically, the RSV diagnostics market is dominated by North America, followed by Europe in 2017. Asia Pacific is estimated to grow at the fastest rate, due to increasing infectious disease burden such as RSV infection, increasing demand for RSV disease diagnosis, and increasing healthcare expenditure in APAC countries.
The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1–43%, Tier 2–35%, Tier 3–22%
• By Designation: C level–62%, Director level–21%, Others–17%
• By Region: North America–32%, Europe–27%, Asia Pacific–22%, Rest of World –19%

The key players in the RSV diagnostics market include bioMérieux (France), Becton Dickinson (US), Abbott (US), Roche (Switzerland), Danaher (US), Thermo Fisher (US), Luminex (US), BioCartis (Belgium), Hologic (US), and Fast Track Diagnostics (Luxembourg).

Research Coverage:
The report analyses the RSV diagnostics market by product, method, end user, and region. Apart from a comprehensive geographic product analysis and market sizing, the report also provides a competitive landscape that covers growth strategies adopted by industry players over the last three years. In addition, the company profiles include the product portfolios, developments, and strategies adopted by prominent market players to maintain and increase their shares in the market. Market research data, current market size, and forecast of the future trends will help key market players and new entrants make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output in order to remain successful.
Key Benefits of Buying the Report:
This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms garner greater market shares. Firms purchasing the report can use one or a combination of the below mentioned five strategies for strengthening their market shares.
The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on the product portfolios of the top players in the RSV diagnostics market.
• Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the RSV diagnostics market.
• Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the RSV diagnostics market.
• Market Development: Comprehensive information about emerging markets. This report analyzes the market for various tissue diagnostics products and services across geographies.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the RSV diagnostics market.

除細動器の世界市場予測（～2022年）

2018年2月23日 // 0 Comments

“The global defibrillators market projected to grow at a CAGR of 3.1%.”The global defibrillators market is expected to reach USD 10.88 billion by 2022 from USD 9.32 billion in 2017, growing at a CAGR of 3.1%. Factors such as technological advancements in defibrillators, rising prevalence of target diseases, growing focus on providing public-access defibrillators, and training & awareness programs on defibrillators are expected to propel the growth of this market. However, issues related to the use of implantable and automated external defibrillators are expected to restrain the growth of the defibrillators market in the forecast period. The defibrillators market has witnessed significant developments in terms of technological advancements and new product developments. The external defibrillators available in the market have provided numerous benefits to patients in terms of ease-of-use, increased patient comfort, and increased accessibility.

“The external defibrillators segment is expected to grow at the highest CAGR during 2017 to 2022.”
On the basis of products, the defibrillators market is classified into implantable cardioverter defibrillators (ICDs) and external defibrillators. The ICDs product segment is bifurcated into transvenous implantable cardioverter defibrillators (T-ICDs) and subcutaneous implantable cardioverter defibrillators (S-ICDs). The T-ICDs segment is further classified into single-chamber ICDs, dual-chamber ICDs, and cardiac resynchronization therapy defibrillators (CRT-Ds). The external defibrillators segment is further classified into manual external defibrillators, automated external defibrillators (AEDs), and wearable cardioverter defibrillators (WCDs). The external defibrillators segment is expected to grow at the highest CAGR in the forecast period, owing to factors such as the growing focus of key market players on developing easy-to-use defibrillators, increasing support from governments to install AEDs at public places, and rising adoption of WCDs.

“The hospitals, clinics, and cardiac centers segment to dominate the global defibrillators market during the forecast period.”
On the basis of end user, the defibrillators market is segmented into hospitals, clinics, and cardiac centers; pre-hospital care settings; public access markets; alternate care facilities; and home care settings. The hospitals, clinics, and cardiac centers segment is estimated to account for the largest share of the defibrillators market in 2017. Growing number of cardiac implant procedures across the globe and the availability of reimbursements across the developed markets are some of the major factors driving the growth of this segment.

“APAC is projected to witness the highest growth during the forecast period.”
The Asia Pacific defibrillators market is expected to grow at the highest CAGR of from 2017 to 2022. Factors such as the rapidly growing aging population, increasing cases of cardiovascular diseases, improving research infrastructure, and growing focus of key market players to expand their presence in this region are driving the growth of the Asia Pacific defibrillators market.

Breakdown of supply-side primary interviews: by company type, designation, and region:
• By Company Type – Tier 1 –31%, Tier 2 –48% and Tier 3 –21%
• By Designation – C-level – 26%, Director-level – 24%, Others – 50%
• By Region – North America – 29%, Europe – 35%, APAC – 21%, RoW – 15%

The key players in the defibrillators market include Medtronic (Ireland), St. Jude Medical (US), Boston Scientific (US), Koninklijke Philips N.V. (Netherlands), ZOLL Medical (US), BIOTRONIK (Germany), Physio-Control (US), Cardiac Science (US), LivaNova (UK), Nihon Kohden (Japan), SCHILLER (Switzerland), Mindray Medical (China), Mediana (South Korea), METRAX (Germany), and METsis (Turkey).

Research Coverage
This report studies the defibrillators market based on product, end user, and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It evaluates opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total market. The report forecasts the revenue of the market segments with respect to four main regions.

Reasons to Buy the Report:
The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on business strategies adopted by the major players in the defibrillators market. The report analyzes the defibrillators market based on product, end user, and region

• Product Development/Innovation: Detailed insights on the upcoming technologies, research and development activities, and product launches in the defibrillators market

• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various defibrillators across geographies

• Market Diversification: Exhaustive information about new defibrillator products, untapped geographies, recent developments, and investments in the defibrillators market

• Competitive Assessment: In-depth assessment of market ranking, strategies, and products of leading players in the defibrillators market

PoC/迅速診断の世界市場予測（～2022年）

2018年2月23日 // 0 Comments

“The point-of-care diagnostics market projected to grow at a CAGR of 10.0%.”The global point-of-care diagnostics market is projected to reach USD 38.13 billion by 2022 from USD 23.71 billion in 2017, at a CAGR of 10.0%. High prevalence of infectious diseases in developing countries, increasing incidence of target diseases, and increasing inclination toward home healthcare across the globe are the factors expected to drive the market during the study period. However, the lack of alignment with definitive central lab methods, certain disadvantages of POC testing over central lab methods, and the reluctance among physicians to change existing diagnostic practices are the key factors that are limiting the growth of this market.

“The glucose monitoring products segment is expected to command the largest share of the POC diagnostics market in 2017.”
On the basis of product, the glucose monitoring products segment is expected to command the largest share of the global POC diagnostics market in 2017. The large share of this segment can be attributed to the growing incidence and prevalence of diabetes across the globe and rising preference for home glucose testing.

“The molecular diagnostics segment is expected to be the fastest-growing segment during the forecast period.”
On the basis of platform, the market is segmented into lateral flow assays, dipsticks, microfluidics, molecular diagnostics, and immunoassays. The molecular diagnostics segment is expected to be the fastest-growing segment during the forecast period. Growing advancements in technology and increasing initiatives of market players for developing POC molecular diagnostic products is propelling the demand for molecular diagnostics.

“Asia Pacific is expected grow at the highest CAGR during the forecast period.”
Geographically, the point-of-care diagnostics market is segmented into North America, Europe, Asia Pacific, and RoW. Asia Pacific is expected to register the highest growth rate during the forecast period due to the growing initiatives by market players, increasing patient population base, and rising number of partnerships and joint ventures in this region.

Breakdown of supply-side primary interviews:
• By Company Type – Tier 1 – 35%, Tier 2 – 45% and Tier 3 – 20%
• By Designation – – C level – 15%, Director level – 30%, Others – 55%
• By Region – North America – 45%, Europe – 20%, APAC – 30%, RoW – 5%

The major players of the point-of-care diagnostics market are Abbott (US), Roche (Switzerland), Siemens (Germany), Danaher (US), Becton, Dickinson, and Company (US), Johnson & Johnson (US), Instrumentation Laboratory (US), PTS Diagnostics (US), Quidel (US), Chembio (US), Sekisui Diagnostics (US), Nova (US), EKF Diagnostics (UK), AccuBioTech (China), and Trinity Biotech (US).

Research Coverage

This report studies the point-of-care diagnostics market based on product, platform, mode, end user, and region. The report also studies factors affecting market growth, it analyzes opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends. The report forecasts the revenue of market segments with respect to the four key regions and respective countries.

Reasons to Buy the Report:

From an insights perspective, this research report has focused on various levels of analysis— market ranking analysis of top players, and company profiles, which together comprise and discuss basic views on the competitive landscape, emerging segments of the point-of-care diagnostics market, and high-growth regions and their drivers, restraints, challenges, and opportunities. The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, will help firms garner greater market shares.